DK1490106T3 - Anvendelse af et lipopeptid eller et lipoprotein som adjuvans ved terapeutiske eller profylaktiske vaccinationer - Google Patents
Anvendelse af et lipopeptid eller et lipoprotein som adjuvans ved terapeutiske eller profylaktiske vaccinationerInfo
- Publication number
- DK1490106T3 DK1490106T3 DK03745782T DK03745782T DK1490106T3 DK 1490106 T3 DK1490106 T3 DK 1490106T3 DK 03745782 T DK03745782 T DK 03745782T DK 03745782 T DK03745782 T DK 03745782T DK 1490106 T3 DK1490106 T3 DK 1490106T3
- Authority
- DK
- Denmark
- Prior art keywords
- adjuvant
- glu
- mucosal
- therapeutic
- galactosidase
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 6
- 238000002255 vaccination Methods 0.000 title abstract 5
- 108010028921 Lipopeptides Proteins 0.000 title abstract 4
- 102000004895 Lipoproteins Human genes 0.000 title abstract 3
- 108090001030 Lipoproteins Proteins 0.000 title abstract 3
- 230000000069 prophylactic effect Effects 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 102000005936 beta-Galactosidase Human genes 0.000 abstract 3
- 108010005774 beta-Galactosidase Proteins 0.000 abstract 3
- DMWMUMWKGKGSNW-OPMCLZTFSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-[(2R)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O)OC(=O)CCCCCCCCCCCCCCC DMWMUMWKGKGSNW-OPMCLZTFSA-N 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 210000004877 mucosa Anatomy 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000003547 immunosorbent Substances 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02007640 | 2002-04-04 | ||
| PCT/EP2003/003497 WO2003084568A2 (de) | 2002-04-04 | 2003-04-03 | Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1490106T3 true DK1490106T3 (da) | 2008-10-27 |
Family
ID=28685840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03745782T DK1490106T3 (da) | 2002-04-04 | 2003-04-03 | Anvendelse af et lipopeptid eller et lipoprotein som adjuvans ved terapeutiske eller profylaktiske vaccinationer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20050276813A1 (da) |
| EP (2) | EP1490106B1 (da) |
| AT (1) | ATE396740T1 (da) |
| AU (1) | AU2003226777B2 (da) |
| CA (1) | CA2480196C (da) |
| CY (1) | CY1108282T1 (da) |
| DE (1) | DE50309916D1 (da) |
| DK (1) | DK1490106T3 (da) |
| ES (1) | ES2307958T3 (da) |
| PT (1) | PT1490106E (da) |
| SI (1) | SI1490106T1 (da) |
| WO (1) | WO2003084568A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19652586A1 (de) * | 1996-12-17 | 1998-06-18 | Biotechnolog Forschung Gmbh | Dhc-Peptid und Mittel |
| KR101604799B1 (ko) | 2005-06-13 | 2016-03-28 | 클리브랜드 바이오랩스, 아이엔씨. | 리포펩티드를 사용하여 아폽토시스에 대항하는 보호방법 |
| EP1776963A1 (en) | 2005-10-19 | 2007-04-25 | Gbf-Gesellschaft Für Biotechnologische Forschung Mbh | Hexosylceramides as adjuvants and their uses in pharmaceutical compositions |
| EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| EP1787660A1 (en) | 2005-11-22 | 2007-05-23 | GBF Gesellschaft für Biotechnologische Forschung mbH | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions |
| US8426163B2 (en) * | 2007-12-07 | 2013-04-23 | National Health Research Institutes | Production of lipidated proteins in E. coli |
| US8466259B2 (en) * | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
| WO2010028246A2 (en) * | 2008-09-05 | 2010-03-11 | Id Biomedical Corporation Of Quebec | Novel compositions and adjuvants |
| US8287880B2 (en) | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
| EP2445927B1 (en) * | 2009-06-22 | 2014-04-23 | National Health Research Institutes | Lipidated tumor- associated antigens and immunotherapeutic compositions |
| DE102009034779A1 (de) | 2009-07-25 | 2011-02-03 | Emc Microcollections Gmbh | Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen |
| EP2338521A1 (en) * | 2009-12-28 | 2011-06-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | Lipopeptide- and lipoprotein-conjugates and its use |
| JP2013542928A (ja) * | 2010-09-30 | 2013-11-28 | フランバックス ソチエタ レスポンサビリタ リミテ | ビロソーム粒子の生成 |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| DE102011018499A1 (de) | 2011-04-23 | 2012-10-25 | Emc Microcollections Gmbh | Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut |
| JP5650780B2 (ja) | 2012-04-04 | 2015-01-07 | 日東電工株式会社 | ワクチン組成物 |
| DE102016005550B4 (de) | 2016-05-09 | 2024-09-26 | Hans-Georg Rammensee | Adjuvans zur lnduzierung einer zellulären lmmunantwort |
| WO2019035605A2 (ko) * | 2017-08-16 | 2019-02-21 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
| KR102098097B1 (ko) | 2017-08-16 | 2020-05-26 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993022343A1 (en) * | 1992-05-01 | 1993-11-11 | The Rockfeller University | Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom |
| DE19652586A1 (de) * | 1996-12-17 | 1998-06-18 | Biotechnolog Forschung Gmbh | Dhc-Peptid und Mittel |
| DE19745522C2 (de) * | 1997-10-15 | 2001-03-22 | Daimler Chrysler Ag | Vorrichtung zur Betätigung eines Gaswechselventiles einer Hubkolbenbrennkraftmaschine |
| DE19822820A1 (de) * | 1998-05-20 | 1999-11-25 | Biotechnolog Forschung Gmbh | Pharmazeutisches Präparat zur Wundbehandlung |
-
2003
- 2003-04-03 AT AT03745782T patent/ATE396740T1/de active
- 2003-04-03 EP EP03745782A patent/EP1490106B1/de not_active Expired - Lifetime
- 2003-04-03 SI SI200331327T patent/SI1490106T1/sl unknown
- 2003-04-03 PT PT03745782T patent/PT1490106E/pt unknown
- 2003-04-03 CA CA2480196A patent/CA2480196C/en not_active Expired - Fee Related
- 2003-04-03 ES ES03745782T patent/ES2307958T3/es not_active Expired - Lifetime
- 2003-04-03 DE DE50309916T patent/DE50309916D1/de not_active Expired - Lifetime
- 2003-04-03 AU AU2003226777A patent/AU2003226777B2/en not_active Ceased
- 2003-04-03 DK DK03745782T patent/DK1490106T3/da active
- 2003-04-03 US US10/509,917 patent/US20050276813A1/en not_active Abandoned
- 2003-04-03 WO PCT/EP2003/003497 patent/WO2003084568A2/de not_active Ceased
- 2003-04-03 EP EP08009600A patent/EP1987841A1/de not_active Withdrawn
-
2008
- 2008-08-22 CY CY20081100896T patent/CY1108282T1/el unknown
-
2013
- 2013-03-22 US US13/848,936 patent/US10905761B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1490106A2 (de) | 2004-12-29 |
| ES2307958T3 (es) | 2008-12-01 |
| SI1490106T1 (sl) | 2009-02-28 |
| PT1490106E (pt) | 2008-09-05 |
| EP1987841A1 (de) | 2008-11-05 |
| ATE396740T1 (de) | 2008-06-15 |
| US20050276813A1 (en) | 2005-12-15 |
| WO2003084568A3 (de) | 2003-12-31 |
| DE50309916D1 (de) | 2008-07-10 |
| AU2003226777A1 (en) | 2003-10-20 |
| CA2480196A1 (en) | 2003-10-16 |
| AU2003226777B2 (en) | 2008-05-29 |
| CA2480196C (en) | 2015-05-12 |
| US20160256542A1 (en) | 2016-09-08 |
| EP1490106B1 (de) | 2008-05-28 |
| CY1108282T1 (el) | 2014-02-12 |
| US10905761B2 (en) | 2021-02-02 |
| WO2003084568A2 (de) | 2003-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108282T1 (el) | Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο | |
| RU2375374C2 (ru) | Домены и эпитопы менингококкового белка nmb1870 | |
| NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
| BR0211437A (pt) | Vacinas que compreendem adjuvantes de alumìnio e histidina | |
| KR950702839A (ko) | 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues) | |
| RU2007103343A (ru) | Вакцинная композиция и способы лечения коронавирусной инфекции | |
| WO2006076410A3 (en) | Li-key/antigenic epitope hybrid peptide vaccines | |
| US20100255033A1 (en) | Non-toxic double mutant forms of pertussis toxin as adjuvants | |
| JP4021146B2 (ja) | Ｒｓｖサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物 | |
| Zeng et al. | Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys | |
| Hancock et al. | CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV) | |
| EP0714307B1 (en) | Vaccine compositions | |
| RU2008145859A (ru) | Вакцина против никотиновой зависимости | |
| WO2004022092A3 (en) | Flagellin peptides as adjuvants for vaccines | |
| WO2019119069A1 (en) | Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent | |
| WO2006076587A3 (en) | Peptides for delivery of mucosal vaccines | |
| Zeng et al. | Lipidation of intact proteins produces highly immunogenic vaccine candidates | |
| NZ552583A (en) | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus | |
| AU2021326938A1 (en) | Compositions of sars-cov-2 vaccines based on the receptor binding domain, expressed as a dimer, and the outer membrane vesicle of meningococcal group b bacteria | |
| Lobaina et al. | Comparative study of the immunogenicity and immunoenhancing effects of two hepatitis B core antigen variants in mice by nasal administration | |
| EP4226947A1 (en) | Covalent conjugates of the sars-cov-2 receptor-binding domain and a carrier protein and vaccine compositions that contain them | |
| WO1993011795A1 (en) | Anti-idiotypic vaccine for protection against bovine respiratory syncytial virus | |
| Plante et al. | Nasal proteosome subunit flu vaccine elicits enhanced mucosal IgA, serum HAI and protection comparable to conventional injectable flu vaccine | |
| WO2023060220A1 (en) | Methods of immunization against coronavirus | |
| KR20220156871A (ko) | 합텐화 코로나바이러스 스파이크 단백질 |